NEX-I
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
201 Songpa-daero, South KoreaPhone Number
+82 269510412Website
www.nex-i.co.krRevenue
<$5 MillionIndustry
About NEX-I
Founded in 2021, NEX-I, Inc. is a pre-clinical stage Korean biotechnology company pioneering the transformative shift in cancer immunotherapy through its proprietary novel target discovery platform. NEX-I identifies and counters conventional treatments often facing resistance from evolving cancer cells, and they set new standards to understand the mechanisms of refractory cancers by targeting the causal factors. With their premier monoclonal antibody, NXI-101, which is designed to modulate the tumor microenvironment by neutralizing the ONCOKINE-1, increasing immune susceptibility of the cancer patients can be expected.Explore more
SIC Code 87,873NAICS Code 54,541Show more
NEX-I Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
NEX-I Tech Stack
A closer look at the technologies used by NEX-I
See more technologies
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NEX-I
Sign Up For FreeTo access detailed company insights
Founded in 2021, NEX-I, Inc. is a pre-clinical stage Korean biotechnology company pioneering the transformative shift in cancer immunotherapy through its proprietary novel target discovery platform. NEX-I identifies and counters conventional treatments often facing resistance from evolving cancer cells, and they set new standards to understand the... Read More
